Genomics and proteomics of bone cancer

Clinical Cancer Research

Volumn 12, Issue 20 PART 2, 2006, Pages

  Marguiles, Aaron G ^a   Klimberg, V Suzanne ^a   Bhattacharrya, Sudeepa ^a   Gaddy, Dana ^a   Suva, Larry J ^a   Roodman, ^b   Berenson, ^b   Pearse, ^b   Vessella, ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLTRANSFERASE; HEPARAN SULFATE; INTERLEUKIN 8;

BONE CANCER; BONE METASTASIS; CELL SURFACE; DISEASE COURSE; GENE EXPRESSION; GENOMICS; HUMAN; MICROARRAY ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

BONE NEOPLASMS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; NEOPLASM METASTASIS; PHENOTYPE; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 33750703626     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1070     Document Type: Review

References (44)

1. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93.
2. Fidler I, Poste G. The pathogenesis of cancer metastasis. Nature 1979;283:139-46.
3. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003;3:453-8.
4. Guise TA, Kozlow WM, Heras-Herzig A, et al. Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer 2005;5 Suppl 2:S46-53.
5. Suva LJ, Winslow GA, Wettenhall RE, et al. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 1987;237:893-6.
6. Guise TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated ostedysis. J Clin Invest 1996;98:1544-9.
7. Bendre M, Gaddy D, Nicholas RW, Suva LJ. Breast cancer metastasis to bone: it is not all about PTHrP. Clin Orthop 2003;Suppl 415:S39-45.
8. Bendre MS, Gaddy-Kurten D, Mon-Foote T, et al. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res 2002;62:5571-9.
9. Boyce B, Yoneda T, Guise T. Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer 1999;6:333-47.
10. Guise TA. Molecular mechanisms of osteolytic bone metastases. Cancer 2000;88:2892-8.
11. Minn AJ, Kang Y, Serganova I, et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005;115:44-55.
12. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-49.
13. Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998;19:18-54.
14. Khanna C, Khan J, Nguyen P, et al. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res 2001;61:3750-9.
15. Bredel M, Bredel C, Juric D, et al. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res 2005;65:8679-89.
16. Sanderson RD, Yang Y, Suva LJ, Kelly T. Heparan sulfate proteoglycans and heparanase-partners in osteolytic tumor growth and metastasis. Matrix Biol 2004;23:341-52.
17. Ramalho-Santos M, Yoon S, Matsuzaki Y, Mulligan RC, Melton DA. "Sternness": transcriptional profiling of embryonic and adult stem cells. Science 2002;298:597-600.
18. Ivanova NB, Dimos JT, Schaniel C, et al. A stem cell molecular signature. Science 2002;298:601-6.
19. Rhodes DR, Tomlins SA, Varambally S, et al. Probabilistic model of the human protein-protein interaction network. Nat Biotechnol 2005;23:951-9.
20. Martin TJ, Moseley JM. Mechanisms in the skeletal complications of breast cancer. Endocr Relat Cancer 2000;7:271-84.
21. Henderson M, Danks J, Moseley J, et al. Parathyroid hormone-related protein production by breast cancers, improved survival, and reduced bone metastases. J Natl Cancer Inst 2001;93:234-7.
22. Henderson MA, Danks JA, Slavin JL, et al. Parathyroid hormone-related protein localization in breast cancers predict improved prognosis. Cancer Res 2006;66:2250-6.
23. Kelly T, Suva LJ, Huang Y, et al. Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases. Cancer Res 2005;65:5778-84.
24. Yang Y, Macleod V, Bendre M, et al. Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood 2005;105:1303-9.
25. Benoy IH, Salgado R, Van Dam P, et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 2004;10:7157-62.
26. Lehrer S, Diamond EJ, Mamkine B, Stone NN, Stock RG. Serum interleukin-8 is elevated in men with prostate cancer and bone metastases. Technol Cancer Res Treat 2004;3:411.
27. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61.
28. Aalinkeel R, Nair MP, Sufrin G, et al. Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells. Cancer Res 2004;64:5311-21.
29. Boucharaba A, Serre CM, Gres S, et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 2004;114:1714-25.
30. Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004;6:447-58.
31. Simpkins F, Czechowicz JA, Liotta L, Kohn EC. SELDI-TOF mass spectrometry for cancer biomarker discovery and serum proteomic diagnostics. Pharmacogenomics 2005;6:647-53.
32. Petricoin EF, Ornstein DK, Liotta LA. Clinical proteomics: applications for prostate cancer biomarker discovery and detection. Urol Oncol 2004;22:322-8.
33. Petricoin EF, Liotta LA. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 2004;15:24-30.
34. Bhattacharyya S, Siegel ER, Petersen GM, et al. Diagnosis of pancreatic cancer using serum proteomic profiling. Neoplasia 2004;6:674-86.
35. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004;96:353-6.
36. Diamandis EP. Point: proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 2003;49:1272-5.
37. Lundquist M, Caspersen MB, Wikstrom P, Forsman M. Discrimination of Francisella tularensis subspecies using surface enhanced laser desorption ionization mass spectrometry and multivariate data analysis. FEMS Microbiol Lett 2005;243:303-10.
38. Izmirlian G. Application of the random forest classification algorithm to a SELDI-TOF proteomics study in the setting of a cancer prevention trial. Ann N Y Acad Sci 2004;1020:154-74.
39. Bhattacharyya S, Epstein J, Suva LJ. Preliminary characterization of serum biomarkers for multiple myeloma with bone metastasis using SELDI-TOF mass spectrometry. J Bone Miner Res 2003;18:S310.
40. Newling DW, Denis L, Vermeylen K. Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer-Genitourinary Group Study 30853. Cancer 1993;72:3793-8.
41. Liotta LA, Lowenthal M, Mehta A, et al. Importance of communication between producers and consumers of publicly available experimental data. J Natl Cancer Inst 2005;97:310-4.
42. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845-67.
43. Ward JB, Jr., Henderson RE. Identification of needs in biomarker research. Environ Health Perspect 1996;104 Suppl 5:895-900.
44. Martin TJ. Osteoblast-derived PTHrP is a physiological regulator of bone formation. J Clin Invest 2005;115:2402-11.